Mahana Therapeutics, a leading provider of digital chronic condition management programs, announced that it has acquired Berlin-based HiDoc Technologies GmbH, operating as Cara Care, a leader in digital digestive healthcare and Asabys portfolio company, member of CataloniaBio & HealthTech.
This combination creates a global company offering the most comprehensive digestive health portfolio currently addressing irritable bowel syndrome (IBS), Irritable Bowel Disorder (IBD), Celiac Disease and Heartburn, with an exciting pipeline focused on Tinnitus, Pruritus, and Vulvodynia.
The combined company operates across the United States, Germany and the United Kingdom with both FDA-cleared and digital wellness programs for IBS and Tinnitus currently prescribed or offered by thousands of healthcare providers and used by tens of thousands of patients worldwide, and an exciting pipeline to reach the millions of patients suffering from IBD, Heartburn, Celiac Disease, Pruritus and Vulvodynia. Mahana is backed by prominent investors including Asabys Partners, JAZZ Venture Partners, Lux Capital, Gurnet Point Capital, Main Street Advisors, KKCG.
The acquisition of Cara Care is expected to accelerate Mahana’s market entry in Europe where the reimbursement of digital programs is outpacing the United States. Cara Care’s IBS prescription-based digital program is currently being prescribed, and reimbursed, to thousands of patients in Germany. The combined entity is now poised to expand its commercialization efforts beyond Germany to France and the United Kingdom as reimbursement of digital programs continues to improve across Europe.
“Cara Care has become the first and only digital therapy specialized in digestive diseases that is reimbursed by the German health system. Germany is a pioneer country in the world in applying regulation to allow healthcare professionals to prescribe and reimburse digital therapies, if they demonstrate a positive impact on patients.” comments Guillem Masferrer, Partner at Asabys, a Spanish venture capital firm and the company's main investor since 2019 through its fund Sabadell Asabys I.
Mahana’s and Cara Care's self-guided, digital chronic condition management programs employ a proprietary cognitive behavioral therapy (CBT) platform that complements consumer health and pharmacological treatments to address high unmet needs associated with digestive, hearing, dermatology, and women’s health chronic conditions. When used with standard of care treatments, these programs can dramatically improve outcomes, patient treatment satisfaction, quality of care and overall patient quality of life while reducing associated provider workload burden.
Comments